Biofrontera Past Earnings Performance
Past criteria checks 3/6
Biofrontera has been growing earnings at an average annual rate of 36.2%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 15.1% per year. Biofrontera's return on equity is 41.3%, and it has net margins of 34.6%.
Key information
36.2%
Earnings growth rate
43.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 15.1% |
| Return on equity | 41.3% |
| Net Margin | 34.6% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Biofrontera makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 32 | 11 | 18 | 7 |
| 30 Jun 22 | 31 | 10 | 24 | 7 |
| 31 Mar 22 | 30 | 15 | 29 | 7 |
| 31 Dec 21 | 29 | 38 | 34 | 7 |
| 30 Sep 21 | 28 | -16 | 28 | 6 |
| 30 Jun 21 | 27 | -16 | 29 | 5 |
| 31 Mar 21 | 29 | -12 | 26 | 5 |
| 31 Dec 20 | 30 | -13 | 28 | 5 |
| 30 Sep 20 | 33 | -17 | 33 | 5 |
| 30 Jun 20 | 33 | -22 | 37 | 5 |
| 31 Mar 20 | 31 | -10 | 45 | 5 |
| 31 Dec 19 | 31 | -7 | 44 | 5 |
| 30 Sep 19 | 26 | 1 | 44 | 4 |
| 30 Jun 19 | 26 | 8 | 40 | 5 |
| 31 Mar 19 | 23 | -8 | 33 | 5 |
| 31 Dec 18 | 21 | -9 | 31 | 4 |
| 30 Sep 18 | 19 | -14 | 24 | 4 |
| 30 Jun 18 | 16 | -15 | 22 | 4 |
| 31 Mar 18 | 14 | -16 | 21 | 4 |
| 31 Dec 17 | 12 | -16 | 20 | 4 |
| 30 Sep 17 | 11 | -18 | 21 | 5 |
| 30 Jun 17 | 9 | -16 | 17 | 5 |
| 31 Mar 17 | 8 | -14 | 14 | 5 |
| 31 Dec 16 | 6 | -11 | 12 | 5 |
| 30 Sep 16 | 4 | -9 | 9 | 4 |
| 30 Jun 16 | 4 | -7 | 8 | 4 |
| 31 Mar 16 | 4 | -9 | 7 | 6 |
| 31 Dec 15 | 4 | -11 | 7 | 6 |
Quality Earnings: B8FE has a large one-off gain of €39.7M impacting its last 12 months of financial results to 30th September, 2022.
Growing Profit Margin: B8FE became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: B8FE has become profitable over the past 5 years, growing earnings by 36.2% per year.
Accelerating Growth: B8FE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: B8FE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: B8FE's Return on Equity (41.3%) is considered outstanding.